Ken Kato

29.6k total citations · 7 hit papers
507 papers, 13.3k citations indexed

About

Ken Kato is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Ken Kato has authored 507 papers receiving a total of 13.3k indexed citations (citations by other indexed papers that have themselves been cited), including 268 papers in Pulmonary and Respiratory Medicine, 261 papers in Surgery and 256 papers in Oncology. Recurrent topics in Ken Kato's work include Esophageal Cancer Research and Treatment (218 papers), Gastric Cancer Management and Outcomes (211 papers) and Cancer Immunotherapy and Biomarkers (109 papers). Ken Kato is often cited by papers focused on Esophageal Cancer Research and Treatment (218 papers), Gastric Cancer Management and Outcomes (211 papers) and Cancer Immunotherapy and Biomarkers (109 papers). Ken Kato collaborates with scholars based in Japan, United States and United Kingdom. Ken Kato's co-authors include Yasuhide Yamada, Yuko Kitagawa, Yasuhiro Shimada, Tetsuya Hamaguchi, Satoru Iwasa, Kei Muro, Takashi Kojima, Hiroyuki Daiko, Yuichiro� Doki and Yasuo Hamamoto and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Ken Kato

470 papers receiving 13.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

2019 751 citations Ken Kato, Keisho Chìn et al. profile →
Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2

2018 400 citations Yuko Kitagawa, Ken Kato et al. Esophagus profile →
Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1

2018 367 citations Yuko Kitagawa, Ken Kato et al. Esophagus profile →
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus

2018 362 citations Manish A. Shah, Takashi Kojima et al. profile →
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

2017 292 citations Yasuo Hamamoto, Ken Kato et al. profile →
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

2018 228 citations Narikazu Boku, Ken Kato et al. Annals of Oncology profile →
A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study.

2022 119 citations Ken Kato, Yoshinori Ito et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Ken Kato	6.2k	5.7k	5.1k	3.2k	1.6k	507	13.3k
Kosei Hirakawa	3.2k 0.5×	3.3k 0.6×	7.6k 1.5×	4.6k 1.5×	3.2k 1.9×	590	14.2k
Eigo Otsuji	3.2k 0.5×	3.7k 0.7×	2.6k 0.5×	5.0k 1.6×	3.8k 2.3×	633	11.4k
Takashi Aikou	4.6k 0.7×	4.3k 0.7×	5.2k 1.0×	3.5k 1.1×	1.7k 1.1×	400	12.5k
Lin Shen	4.2k 0.7×	7.1k 1.2×	7.4k 1.4×	4.1k 1.3×	2.0k 1.2×	487	15.4k
Yoshiharu Sakai	4.1k 0.7×	3.0k 0.5×	5.4k 1.0×	3.2k 1.0×	1.6k 1.0×	409	11.8k
Michiaki Unno	5.9k 0.9×	3.2k 0.6×	7.6k 1.5×	3.4k 1.1×	1.8k 1.1×	682	14.0k
Hisahiro Matsubara	5.5k 0.9×	4.8k 0.8×	2.7k 0.5×	3.5k 1.1×	1.7k 1.0×	506	12.0k
Akimasa Nakao	6.0k 1.0×	4.1k 0.7×	7.3k 1.4×	3.7k 1.2×	2.2k 1.3×	554	15.2k
Masakazu Yashiro	2.0k 0.3×	2.4k 0.4×	4.6k 0.9×	5.3k 1.7×	2.6k 1.6×	364	10.9k
Eiji Oki	3.3k 0.5×	3.5k 0.6×	4.5k 0.9×	3.5k 1.1×	1.8k 1.1×	617	10.9k

Countries citing papers authored by Ken Kato

Since Specialization

Citations

This map shows the geographic impact of Ken Kato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Kato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Kato more than expected).

Fields of papers citing papers by Ken Kato

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Kato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Kato. The network helps show where Ken Kato may publish in the future.

Co-authorship network of co-authors of Ken Kato

This figure shows the co-authorship network connecting the top 25 collaborators of Ken Kato. A scholar is included among the top collaborators of Ken Kato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Kato. Ken Kato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yoshida, Tatsuya, Kuniko Sunami, Takafumi Koyama, et al.. (2025). Upfront liquid biopsy in patients with advanced solid tumors who were not feasible for tissue-based next-generation sequencing. Japanese Journal of Clinical Oncology. 55(7). 720–728. 1 indexed citations

Sakane, Naoki, Ken Kato, Rika Araki, et al.. (2025). Associations between clustering of hypoglycemic symptoms, psychological traits, and problem-solving abilities in adults with type 1 diabetes: baseline data analysis of the PR-IAH study. Diabetology International. 16(2). 294–302.

Xu, Jianming, Ken Kato, Yongqian Shu, et al.. (2024). 395MO Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306. Annals of Oncology. 35. S159–S159. 1 indexed citations

Yamamoto, Shun, Yoshitaka Honma, Hidekazu Hirano, et al.. (2024). Retrospective Analysis of Definitive Chemoradiotherapy With FOLFOX in Patients With Esophageal Cancer Intolerant to Cisplatin. In Vivo. 38(2). 761–766. 2 indexed citations

Sun, Jong‐Mu, Antoine Adenis, Peter C. Enzinger, et al.. (2024). LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma. Future Oncology. 20(35). 2709–2721. 2 indexed citations

Ooki, Akira, Kei Muro, Kazumi Nishino, et al.. (2024). Phase 1b study of futibatinib plus pembrolizumab with or without chemotherapy in patients with esophageal carcinoma: Updated results of antitumor activity.. Journal of Clinical Oncology. 42(16_suppl). 4047–4047.

Sato, Jun, Yuta Maruki, Kenjiro Namikawa, et al.. (2024). Early combination with mycophenolate mofetil for immune-related hepatitis in patients with solid tumors treated with immune checkpoint inhibitors.. Journal of Clinical Oncology. 42(16_suppl). 12133–12133. 2 indexed citations

Iwasa, Satoru, Kengo Nagashima, Shun Yamamoto, et al.. (2023). Progression patterns and site‐specific responses in advanced gastric cancer patients treated with nivolumab. Cancer Medicine. 12(8). 9322–9331. 2 indexed citations

Morizane, Chigusa, Nozomu Machida, Yoshitaka Honma, et al.. (2023). 1203P Role of tumor markers before or during chemotherapy for poorly differentiated neuroendocrine carcinomas of the digestive system: An exploratory analysis of JCOG1213. Annals of Oncology. 34. S709–S709. 1 indexed citations

10.

Kato, Ken, Takao Togawa, Koichi Ito, et al.. (2023). Clinicopathologic Features, Genetics, Treatment, and Long-Term Outcomes in Japanese Children and Young Adults with Benign Recurrent Intrahepatic Cholestasis: A Multicenter Study. Journal of Clinical Medicine. 12(18). 5979–5979. 3 indexed citations

11.

Ajani, Jaffer A., Farid El Hajbi, David Cunningham, et al.. (2023). Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study. ESMO Open. 9(1). 102202–102202. 3 indexed citations

12.

Hamamoto, Yasuo, Kentaro Murakami, Ken Kato, & Yuko Kitagawa. (2022). Management of elderly patients with esophageal squamous cell cancer. Japanese Journal of Clinical Oncology. 52(8). 816–824. 9 indexed citations

13.

Ura, Takashi, Shuichi Hironaka, Yasuhiro Tsubosa, et al.. (2022). Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807. Esophagus. 20(2). 272–280. 6 indexed citations

14.

Yamamoto, Shun & Ken Kato. (2020). Immuno-Oncology for Esophageal Cancer. Future Oncology. 16(32). 2673–2681. 19 indexed citations

15.

Hironaka, Shuichi, Azusa Komori, Ryunosuke Machida, et al.. (2020). The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage II/III esophageal cancer: an exploratory analysis of JCOG0909. Esophagus. 17(4). 417–424. 8 indexed citations

16.

Urabe, Fumihiko, Juntaro Matsuzaki, Yusuke Yamamoto, et al.. (2019). Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer. Clinical Cancer Research. 25(10). 3016–3025. 87 indexed citations

17.

Otsuka, Ryo, Satoru Iwasa, Takako Yanai, et al.. (2019). Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy with paclitaxel for advanced gastric cancer. International Journal of Clinical Oncology. 25(4). 595–601. 5 indexed citations

18.

Shiino, Sho, Juntaro Matsuzaki, Akihiko Shimomura, et al.. (2018). Serum miRNA–based Prediction of Axillary Lymph Node Metastasis in Breast Cancer. Clinical Cancer Research. 25(6). 1817–1827. 47 indexed citations

19.

Sakakibara, Hiroyuki, et al.. (2016). Whey Protein-hydrolyzed Peptides Diminish Hepatic Lipid Levels in Rats Consuming High-sucrose Diets. Food Science and Technology Research. 22(5). 631–638. 9 indexed citations

20.

Tada, Kohei, Shigehisa Kitano, Hirokazu Shoji, et al.. (2016). Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients. Cancer Immunology Research. 4(7). 592–599. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact